N o 344-Salpingectomie opportuniste et autres méthodes pour réduire le risque de cancer de l'ovaire, de la trompe de Fallope et du péritoine dans la population générale

Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2015 Canadian Cancer Society's Advisory Committee on Cancer Statistics, 2014 Kurman, 2010, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, Am J Surg Pathol, 34, 433, 10.1097/PAS.0b013e3181cf3d79 Committee on Gynecologic Practice, 2015, Committee opinion no. 620: salpingectomy for ovarian cancer prevention, Obstet Gynecol, 125, 279, 10.1097/01.AOG.0000459871.88564.09 2013 Polcher, 2015, Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO, Arch Gynecol Obstet, 292, 231, 10.1007/s00404-015-3697-y Kurman, 2013, Origin and molecular pathogenesis of ovarian high-grade serous carcinoma, Ann Oncol, 24, x16, 10.1093/annonc/mdt463 Gilks, 2010, Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma, J Oncol, 2010, 740968 Kobel, 2008, Critical molecular abnormalities in highgrade serous carcinoma of the ovary, Expert Rev Mol Med, 10, e22, 10.1017/S146239940800077X Ahmed, 2010, Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary, J Pathol, 221, 49, 10.1002/path.2696 Dann, 2012, BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer, Gynecol Oncol, 125, 677, 10.1016/j.ygyno.2012.03.006 Hennessy, 2010, Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer, J Clin Oncol, 28, 3570, 10.1200/JCO.2009.27.2997 McAlpine, 2012, BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma, Mod Pathol, 25, 740, 10.1038/modpathol.2011.211 Prat, 2005, Hereditary ovarian cancer, Hum Pathol, 36, 861, 10.1016/j.humpath.2005.06.006 Fathalla, 1971, Incessant ovulation-a factor in ovarian neoplasia?, Lancet, 2, 163, 10.1016/S0140-6736(71)92335-X Cramer, 1983, Determinants of ovarian cancer risk. I. Reproductive experiences and family history, J Natl Cancer Inst, 71, 711 Riska, 2007, Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004, Int J Cancer, 120, 1351, 10.1002/ijc.22491 Sedlis, 1961, Primary carcinoma of the fallopian tube, Obstet Gynecol Surv, 16, 209, 10.1097/00006254-196104000-00022 Yoonessi, 1979, Carcinoma of the fallopian tube, Obstet Gynecol Surv, 34, 257, 10.1097/00006254-197904000-00001 Demopoulos, 2001, Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study, Int J Gynecol Pathol, 20, 128, 10.1097/00004347-200104000-00003 Mutch, 2014, 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer, Gynecol Oncol, 133, 401, 10.1016/j.ygyno.2014.04.013 Singh, 2014, Assignment of primary site in highgrade serous tubal, ovarian and peritoneal carcinoma: a proposal, Histopathology, 65, 149, 10.1111/his.12419 Nelson, 2014, Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation, Ann Intern Med, 160, 255, 10.7326/M13-1684 Rebbeck, 2009, Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers, J Natl Cancer Inst, 101, 80, 10.1093/jnci/djn442 Finch, 2006, Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers, Gynecol Oncol, 100, 58, 10.1016/j.ygyno.2005.06.065 Leeper, 2002, Pathologic findings in prophylactic oophorectomy specimens in high-risk women, Gynecol Oncol, 87, 52, 10.1006/gyno.2002.6779 Olivier, 2004, Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up, Br J Cancer, 90, 1492, 10.1038/sj.bjc.6601692 Callahan, 2007, Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction, J Clin Oncol, 25, 3985, 10.1200/JCO.2007.12.2622 Cass, 2005, BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?, Obstet Gynecol, 106, 1327, 10.1097/01.AOG.0000187892.78392.3f Powell, 2005, Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy, J Clin Oncol, 23, 127, 10.1200/JCO.2005.04.109 Medeiros, 2006, The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome, Am J Surg Pathol, 30, 230, 10.1097/01.pas.0000180854.28831.77 Shaw, 2009, Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers, Mod Pathol, 22, 1133, 10.1038/modpathol.2009.89 Casey, 2004, Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations, Fam Cancer, 3, 265, 10.1007/s10689-004-9554-y Kindelberger, 2007, Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship, Am J Surg Pathol, 31, 161, 10.1097/01.pas.0000213335.40358.47 Salvador, 2008, Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma, Gynecol Oncol, 110, 408, 10.1016/j.ygyno.2008.05.010 Seidman, 2015, Serous tubal intraepithelial carcinoma localizes to the tubalperitoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer), Int J Gynecol Pathol, 34, 112, 10.1097/PGP.0000000000000123 Carlson, 2008, Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention, J Clin Oncol, 26, 4160, 10.1200/JCO.2008.16.4814 Seidman, 2011, “Primary peritoneal” high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer, Gynecol Oncol, 120, 470, 10.1016/j.ygyno.2010.11.020 Lee, 2007, A candidate precursor to serous carcinoma that originates in the distal fallopian tube, J Pathol, 211, 26, 10.1002/path.2091 Jarboe, 2008, Serous carcinogenesis in the fallopian tube: a descriptive classification, Int J Gynecol Pathol, 27, 1, 10.1097/pgp.0b013e31814b191f Bahar-Shany, 2014, Exposure of fallopian tube epithelium to follicular fluid mimics carcinogenic changes in precursor lesions of serous papillary carcinoma, Gynecol Oncol, 132, 322, 10.1016/j.ygyno.2013.12.015 Fleming, 2006, Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses, Mol Cell Endocrinol, 247, 4, 10.1016/j.mce.2005.09.014 Ness, 1999, Possible role of ovarian epithelial inflammation in ovarian cancer, J Natl Cancer Inst, 91, 1459, 10.1093/jnci/91.17.1459 Lattuada, 2015, Fimbrial cells exposure to catalytic iron mimics carcinogenic changes, Int J Gynecol Cancer, 25, 389, 10.1097/IGC.0000000000000379 Seidman, 2002, Salpingitis,salpingoliths, and serous tumors of the ovaries: is there a connection?, Int J Gynecol Pathol, 21, 101, 10.1097/00004347-200204000-00001 Idahl, 2011, Chlamydia trachomatis and Mycoplasma genitalium plasma antibodies in relation to epithelial ovarian tumors, Infect Dis Obstet Gynecol, 2011, 824627, 10.1155/2011/824627 Ness, 2008, Chlamydia trachomatis serology in women with and without ovarian cancer, Infect Dis Obstet Gynecol, 2008, 219672, 10.1155/2008/219672 Sieh, 2013, Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies, Int J Epidemiol, 42, 579, 10.1093/ije/dyt042 Kobayashi, 2009, Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review), Oncol Rep, 22, 233 Kobayashi, 2007, Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan, Int J Gynecol Cancer, 17, 37, 10.1111/j.1525-1438.2006.00754.x Kocbek, 2015, Panels of cytokines and other secretory proteins as potential biomarkers of ovarian endometriosis, J Mol Diagn, 17, 325, 10.1016/j.jmoldx.2015.01.006 Faber, 2013, Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer, Cancer Causes Control, 24, 2197, 10.1007/s10552-013-0296-8 Havrilesky, 2013, Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and metaanalysis, Obstet Gynecol, 122, 139, 10.1097/AOG.0b013e318291c235 Yang, 2012, Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study, Int J Cancer, 131, 938, 10.1002/ijc.26469 Cibula, 2011, Tubal ligation and the risk of ovarian cancer: review and meta-analysis, Hum Reprod Update, 17, 55, 10.1093/humupd/dmq030 Rice, 2013, Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England case-control study, Int J Cancer, 133, 2415, 10.1002/ijc.28249 Parker, 2009, Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study, Obstet Gynecol, 113, 1027, 10.1097/AOG.0b013e3181a11c64 Atsma, 2006, Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis, Menopause, 13, 265, 10.1097/01.gme.0000218683.97338.ea Crane, 2014, Dietary intake and ovarian cancer risk: a systematic review, Cancer Epidemiol Biomarkers Prev, 23, 255, 10.1158/1055-9965.EPI-13-0515 Merritt, 2014, Dietary fat intake and risk of epithelial ovarian cancer by tumour histology, Br J Cancer, 110, 1392, 10.1038/bjc.2014.16 Lee, 2013, Preserved foods associated with increased risk of ovarian cancer, Gynecol Oncol, 129, 570, 10.1016/j.ygyno.2013.03.016 Aschebrook-Kilfoy, 2012, Epithelial ovarian cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study, Eur J Cancer Prev, 21, 65, 10.1097/CEJ.0b013e328347622f Olsen, 2007, Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis, Eur J Cancer, 43, 690, 10.1016/j.ejca.2006.11.010 Olsen, 2013, Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium, Endocr Relat Cancer, 20, 251, 10.1530/ERC-12-0395 Torres, 2013, Nutritional status, CT body composition measures and survival in ovarian cancer, Gynecol Oncol, 129, 548, 10.1016/j.ygyno.2013.03.003 Febbraro, 2014, Old drug, new trick: repurposing metformin for gynecologic cancers?, Gynecol Oncol, 135, 614, 10.1016/j.ygyno.2014.10.011 Stine, 2014, Metformin and gynecologic cancers, Obstet Gynecol Surv, 69, 477, 10.1097/OGX.0000000000000092 Dilokthornsakul, 2013, The effects of metformin on ovarian cancer: a systematic review, Int J Gynecol Cancer, 23, 1544, 10.1097/IGC.0b013e3182a80a21 Terry, 2013, Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls, Cancer Prev Res (Phila), 6, 811, 10.1158/1940-6207.CAPR-13-0037 Huncharek, 2011, Perineal talc use and ovarian cancer risk: a case study of scientific standards in environmental epidemiology, Eur J Cancer Prev, 20, 501, 10.1097/CEJ.0b013e3283476242 Wentzensen, 2014, Talc use and ovarian cancer: epidemiology between a rock and a hard place, J Natl Cancer Inst, 106, 10.1093/jnci/dju260 Houghton, 2014, Perineal powder use and risk of ovarian cancer, J Natl Cancer Inst, 106, 10.1093/jnci/dju208 Tsoref, 2014, Aspirin in prevention of ovarian cancer: are we at the tipping point?, J Natl Cancer Inst, 106, djt453, 10.1093/jnci/djt453 Trabert, 2014, Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium, J Natl Cancer Inst, 106, djt431, 10.1093/jnci/djt431 Baandrup, 2014, Prescription use of paracetamol and risk for ovarian cancer in Denmark, J Natl Cancer Inst, 106, dju111, 10.1093/jnci/dju111 Buys, 2011, Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial, JAMA, 305, 2295, 10.1001/jama.2011.766 Jacobs, 2016, Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial, Lancet, 387, 945, 10.1016/S0140-6736(15)01224-6 Kobayashi, 2008, A randomized study of screening for ovarian cancer: a multicenter study in Japan, Int J Gynecol Cancer, 18, 414, 10.1111/j.1525-1438.2007.01035.x Diergaarde, 2014, Use of fertility drugs and risk of ovarian cancer, Curr Opin Obstet Gynecol, 26, 125, 10.1097/GCO.0000000000000060 Trabert, 2013, Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort, Fertil Steril, 100, 1660, 10.1016/j.fertnstert.2013.08.008 Asante, 2013, Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study, Fertil Steril, 99, 2031, 10.1016/j.fertnstert.2013.02.010 Brinton, 2013, In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services, Fertil Steril, 99, 1189, 10.1016/j.fertnstert.2012.12.029 Siristatidis, 2013, Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer-a systematic review and meta-analysis, Hum Reprod Update, 19, 105, 10.1093/humupd/dms051 Nezhat, 2015, New insights in the pathophysiology of ovarian cancer and implications for screening and prevention, Am J Obstet Gynecol, 213, 262, 10.1016/j.ajog.2015.03.044 Melin, 2013, Hormonal and surgical treatments for endometriosis and risk of epithelial ovarian cancer, Acta Obstet Gynecol Scand, 92, 546, 10.1111/aogs.12123 Robert, 2015, Success and complications of salpingectomy at the time of vaginal hysterectomy, J Minim Invasive Gynecol, 22, 864, 10.1016/j.jmig.2015.04.012 Danis, 2016, Postpartum permanent sterilization: could bilateral salpingectomy replace bilateral tubal ligation?, J Minim Invasive Gynecol, 23, 928, 10.1016/j.jmig.2016.05.006 Minig, 2015, Surgical outcomes and complications of prophylactic salpingectomy at the time of benign hysterectomy in premenopausal women, J Minim Invasive Gynecol, 22, 653, 10.1016/j.jmig.2015.02.013 Morelli, 2013, Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere, Gynecol Oncol, 129, 448, 10.1016/j.ygyno.2013.03.023 Vorwergk, 2014, Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate, J Cancer Res Clin Oncol, 140, 859, 10.1007/s00432-014-1622-6 Guldberg, 2013, Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977-2010, BMJ Open, 3, 10.1136/bmjopen-2013-002845 Yoon, 2016, Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis, Eur J Cancer, 55, 38, 10.1016/j.ejca.2015.12.003 Falconer, 2015, Ovarian cancer risk after salpingectomy: a nationwide population-based study, J Natl Cancer Inst, 107, 10.1093/jnci/dju410 McAlpine, 2014, Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention, Am J Obstet Gynecol, 210, 471.e1, 10.1016/j.ajog.2014.01.003